Pfizer Inc. (PFE) Stock Price: $25.70+0.08 (+0.31%)
The total return cagr for Pfizer Inc. (PFE) stock is 14.76% over the past 12 months. The 3 year average growth rate is -7.34% and the 5 year cagr is -3.54%. Total return includes dividends reinvested.
The closing share price for Pfizer Inc. (PFE) stock was $25.70 for Tuesday, June 9, 2026, up +0.31% from the previous day.
PFE Price Chart
PFE Key Metrics
See All MetricsPFE Earnings Preview
Next Earnings Date
Jul 29, 2026
50 days away
EPS Estimate
0.68
Revenue Est.
$14.44B
Last Quarter Results
EPS
$0.75
vs Estimate
$0.72
Revenue
$14.45B
vs Estimate
$13.84B
PFE Analyst Ratings
Consensus Rating
Based on 27 analysts
Average Price Target
$29.19
+13.6% upside
Low
$24.00
Current
$25.70
High
$36.00
PFE Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2026 | N/A | $0.72 | N/A | 13 |
| Q2 2026 | N/A | $0.68 | N/A | 12 |
| Q3 2026 | N/A | $0.85 | N/A | 11 |
| Q4 2026 | N/A | $0.69 | N/A | 9 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $2.83 | N/A | 14 |
| FY 2028 | N/A | $2.43 | N/A | 6 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2026 | N/A | $13.84B | N/A | 13 |
| Q2 2026 | N/A | $14.44B | N/A | 12 |
| Q3 2026 | N/A | $16.23B | N/A | 11 |
| Q4 2026 | N/A | $16.78B | N/A | 9 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $59.20B | N/A | 14 |
| FY 2028 | N/A | $54.70B | N/A | 6 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
PFE Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1PFE | $146.48B | $25.70 | +0.31% | +14.76% | -3.54% | +1.93% |
PFE Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla